AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program with Encouraging Preliminary Safety Data.
ByAinvest
Monday, Oct 6, 2025 7:33 am ET1min read
Marker Therapeutics has initiated a Phase 1 RAPID study to investigate its Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product. The first patient treated in the study showed the OTS product was well-tolerated, with safety data consistent with other MAR-T cell studies. Marker aims to remove the bottleneck of individualized cell therapy manufacturing and provide a fast treatment option for patients with aggressive diseases. The company has secured non-dilutive funding to support the clinical investigation of the OTS product.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet